Table 2. The patients’ baseline characteristics and patients’ clinical parameters stratified by NLR, PLR, LMR and AGR.
| Case | NLR n (%) | PLR n (%) | LMR n (%) | AGR n (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NO.(100%) | ≤ 2.7 | > 2.7 | p | ≤ 215.8 | > 215.8 | p | ≤ 2.8 | > 2.8 | p | < 1.5 | ≥ 1.5 | p | |
| Age (years) | 0.002* | 0.003* | 0.023* | 0.216 | |||||||||
| ≤ 60 | 116 (89.9) | 61 (52.6) | 55 (47.4) | 86 (74.1) | 30 (25.9) | 34 (29.3) | 82 (70.7) | 62 (53.4) | 54 (46.6) | ||||
| > 60 | 13 (10.1) | 1 (7.7) | 12 (92.3) | 4 (30.8) | 9 (69.2) | 8 (61.5) | 5 (38.5) | 9 (69.2) | 4 (30.8) | ||||
| Gender | 0.035* | 0.112 | 0.097 | 0.263 | |||||||||
| Male | 74 (57.4) | 30 (40.5) | 44 (59.5) | 48 (64.9) | 26 (35.1) | 28 (37.8) | 46 (62.2) | 43 (58.1) | 31 (41.9) | ||||
| Female | 55 (42.6) | 32 (58.2) | 23 (41.8) | 42 (76.4) | 13 (23.6) | 14 (25.5) | 41 (74.5) | 28 (50.9) | 27 (49.1) | ||||
| Treatment history | 0.202 | 0.486 | 0.025* | 0.489 | |||||||||
| Primary | 101 (78.3) | 51 (50.5) | 50 (49.5) | 71 (70.3) | 30 (29.7) | 28 (27.7) | 73 (72.3) | 55 (54.5) | 46 (45.5) | ||||
| Recurrent | 28 (21.7) | 11 (39.3) | 17 (60.7) | 19 (67.9) | 9 (32.1) | 14 (50.0) | 14 (50.0) | 16 (57.1) | 12 (42.9) | ||||
| Duration of symptoms | 0.101 | 0.028* | 0.100 | 0.046* | |||||||||
| ≤ 12 | 32 (24.8) | 19 (59.4) | 13 (40.6) | 27 (84.4) | 34 (15.6) | 7 (21.9) | 25 (78.1) | 13 (40.6) | 19 (59.4) | ||||
| > 12 | 97 (75.2) | 43 (44.3) | 54 (55.7) | 63 (64.9) | 9 (35.1) | 35 (36.1) | 62 (63.9) | 58 (59.8) | 39 (40.2) | ||||
| Preoperative Frankel score | 0.325 | 0.479 | 0.102 | 0.511 | |||||||||
| A-C | 41 (31.8) | 18 (43.9) | 23 (56.1) | 28 (68.3) | 13 (31.7) | 17 (41.5) | 24 (58.5) | 23 (56.1) | 18 (43.9) | ||||
| D-E | 88 (68.2) | 44 (50.0) | 44 (50.0) | 62 (70.5) | 26 (29.5) | 25 (28.4) | 63 (71.6) | 48 (54.5) | 40 (45.5) | ||||
| Tumor location | 0.631 | 0.657 | 0.246 | 0.626 | |||||||||
| Cervical | 36 (27.9) | 16 (44.4) | 20 (55.6) | 25 (69.4) | 11 (30.6) | 12 (33.3) | 24 (66.7) | 20 (55.6) | 16 (45.7) | ||||
| Thoracic | 44 (34.1) | 20 (45.5) | 24 (54.5) | 32 (72.7) | 12 (27.3) | 15 (34.1) | 29 (65.9) | 25 (56.8) | 19 (43.2) | ||||
| Lumbar | 22 (17.1) | 10 (45.5) | 12 (54.5) | 13 (59.1) | 9 (40.9) | 10 (45.5) | 12 (54.5) | 13 (59.1) | 9 (40.9) | ||||
| Sacrum | 27 (20.9) | 16 (59.3) | 11 (40.7) | 20 (74.1) | 7 (25.9) | 5 (18.5) | 22 (81.5) | 13 (48.1) | 14 (51.9) | ||||
| Involved segment | 0.365 | 0.453 | 0.432 | 0.318 | |||||||||
| Monosegment | 80 (62.0) | 37 (46.2) | 43 (53.8) | 55 (68.8) | 25 (31.3) | 27 (33.8) | 53 (66.3) | 46 (57.5) | 34 (42.5) | ||||
| Multisegment | 49 (38.0) | 25 (51.0) | 24 (49.0) | 35 (71.4) | 14 (28.6) | 15 (30.6) | 34 (69.4) | 25 (51.0) | 24 (49.0) | ||||
| Tumor length (cm) | 0.015* | 0.009* | 0.054 | 0.087 | |||||||||
| ≤ 3 | 96 (74.4) | 52 (54.2) | 44 (45.8) | 73 (76.0) | 23 (24.0) | 27 (28.1) | 69 (71.9) | 49 (51.01) | 47 (49.0) | ||||
| > 3 | 33 (25.6) | 10 (30.3) | 23 (69.7) | 17 (51.5) | 16 (48.5) | 15 (45.5) | 18 (54.5) | 22 (66.7) | 11 (33.3) | ||||
| Preoperative embolization | 0.469 | 0.417 | 0.352 | 0.385 | |||||||||
| Yes | 66 (51.2) | 31 (47.0) | 35 (53.0) | 45 (68.2) | 21 (31.8) | 23 (34.8) | 43 (65.2) | 35 (53.0) | 31 (47.0) | ||||
| No | 63 (48.8) | 31 (49.2) | 32 (50.8) | 45 (71.4) | 18 (28.6) | 19 (30.2) | 44 (69.8) | 36 (57.1) | 27 (42.9) | ||||
| Enneking staging | 0.259 | 0.604 | 0.631 | 0.478 | |||||||||
| I | 15 (11.6) | 5 (33.3) | 10 (66.7) | 11 (73.3) | 4 (26.7) | 6 (40.0) | 9 (60.0) | 7 (46.7) | 8 (53.3) | ||||
| II | 78 (60.5) | 38 (48.7) | 40 (51.3) | 55 (70.5) | 23 (29.5) | 23 (29.5) | 55 (70.5) | 43 (55.1) | 35 (44.9) | ||||
| III | 36 (27.9) | 19 (52.8) | 17 (47.2) | 24 (66.7) | 12 (33.3) | 13 (36.1) | 23 (63.9) | 21 (58.3) | 15 (41.7) | ||||
| Bisphosphonate treatment | 0.018* | 0.008* | 0.001* | 0.033* | |||||||||
| Yes | 72 (55.8) | 41 (56.9) | 31 (43.1) | 57 (79.2) | 15 (20.8) | 15 (20.8) | 57 (79.2) | 34 (47.2) | 38 (52.8) | ||||
| No | 57 (44.2) | 21 (36.8) | 36 (63.2) | 33 (57.9) | 24 (42.1) | 27 (47.4) | 30 (52.6) | 37 (64.9) | 20 (35.1) | ||||
| Adjuvant radiotherapy | 0.356 | 0.421 | 0.461 | 0.453 | |||||||||
| Yes | 53 (41.1) | 27 (50.9) | 26 (49.1) | 38 (71.7) | 15 (28.3) | 18 (34.0) | 35 (66.0) | 30 (56.6) | 23 (43.4) | ||||
| No | 76 (58.9) | 35 (46.1) | 41 (53.9) | 52 (68.4) | 24 (31.6) | 24 (31.6) | 52 (68.4) | 41 (53.9) | 35 (46.1) | ||||
NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; LMR: lymphocyte-to-monocyte ratio; AGR: albumin/globulin ratio
*: p value ≤ 0.05.